References
- 1Sendo T, Sakai N, Itoh Y, Ikesue H, Kobayashi H, Hirakawa T, et al. Incidence and risk factors for paclitaxel hypersensitivity during ovarian cancer chemotherapy. Cancer Chemother Pharmacol. 2005; 56:91-6.10.1007/s00280-004-0924-915791461SendoTSakaiNItohYIkesueHKobayashiHHirakawaTet alIncidence and risk factors for paclitaxel hypersensitivity during ovarian cancer chemotherapyCancer Chemother Pharmacol200556916
- 2Taxol injection (package insert). Princeton: Bristol-Myers Squibb Company; 2007.Taxol injection (package insert)PrincetonBristol-Myers Squibb Company2007
- 3Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med. 2008; 358: 1663-71.1842049910.1056/NEJMoa0707056SparanoJAWangMMartinoSJonesVPerezEASaphnerTet alWeekly paclitaxel in the adjuvant treatment of breast cancerN Engl J Med2008358166371
- 4Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007; 357:2666-76.10.1056/NEJMoa07211318160686MillerKWangMGralowJDicklerMCobleighMPerezEAet alPaclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancerN Engl J Med2007357266676
- 5Köppler H, Heymanns J, Weide R. Dose reduction of steroid premedication for paclitaxel: no increase of hypersensitivity reactions. Onkologie. 2001; 24:283-5. [Article in English, German]KöpplerHHeymannsJWeideRDose reduction of steroid premedication for paclitaxelno increase of hypersensitivity reactionsOnkologie200124[Article in English, German]
- 6Berger MJ, Dunlea LJ, Rettig AE, Lustberg MB, Phillips GS, Shapiro CL. Feasibility of stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction. Support Care Cancer. 2012; 20:1991-7.10.1007/s00520-011-1303-922089428BergerMJDunleaLJRettigAELustbergMBPhillipsGSShapiroCLFeasibility of stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reactionSupport Care Cancer20122019917
- 7Berger MJ, Vargo C, Vincent M, Shaver K, Phillips G, Layman R, et al. Stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction. Support Care Cancer. 2015; 23:2019-24.2551975610.1007/s00520-014-2556-xBergerMJVargoCVincentMShaverKPhillipsGLaymanRet alStopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reactionSupport Care Cancer201523201924
- 8Piovano E, Pivetta E, Modaffari P, Martra F, Baima Poma C, Perotto S, et al. A search for predictive factors for hypersensitivity reactions to paclitaxel and platinum salts in chemotherapy for gynecologic pelvic neoplasms. Gynecol Obstet Invest. 2012; 74: 21-7.10.1159/00033677222652565PiovanoEPivettaEModaffariPMartraFBaimaPoma CPerottoSet alA search for predictive factors for hypersensitivity reactions to paclitaxel and platinum salts in chemotherapy for gynecologic pelvic neoplasmsGynecol Obstet Invest201274217
- 9Sui M, Chen F, Chen Z, Fan W. Glucocorticoids interfere with therapeutic efûcacy of paclitaxel against human breast and ovarian xenograft tumors. Int J Cancer. 2006; 119:712-7.10.1002/ijc.2174316496381SuiMChenFChenZFanWGlucocorticoids interfere with therapeutic efûcacy of paclitaxel against human breast and ovarian xenograft tumorsInt J Cancer20061197127
- 10Hou WJ, Guan JH, Dong Q, Han YH, Zhang R. Dexamethasone inhibits the effect of paclitaxel on human ovarian carcinoma xenografts in nude mice. Eur Rev Med Pharmacol Sci. 2013; 17:2902-8.24254559HouWJGuanJHDongQHanYHZhangRDexamethasone inhibits the effect of paclitaxel on human ovarian carcinoma xenografts in nude miceEur Rev Med Pharmacol Sci20131729028